Evidence map›Paper›PMID 28381518›Full record

ArticleBioscience reports2017

MicroRNA-379 inhibits the proliferation, migration and invasion of human osteosarcoma cells by targetting EIF4G2.

Xi Xie, Yu-Sheng Li, Wen-Feng Xiao, Zhen-Han Deng, Hong-Bo He, Qing Liu, Wei Luo

RetractedErratum issuedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Bioscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. MIR-379-5p Expression in Endometrial Cancer and Its Correlation with ROR1 Expression.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xi XieDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.
Yu-Sheng LiDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China liyusheng0731@sina.com luowei0928@126.com.
Wen-Feng XiaoDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.
Zhen-Han DengDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.
Hong-Bo HeDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.
Qing LiuDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.
Wei LuoDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, P.R. China liyusheng0731@sina.com luowei0928@126.com.
Xiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is an aggressive malignant mesenchymal neoplasm amongst adolescents. The aim of the present study was to explore the various modes of action that

Indexed as

Cell Line, TumorCell MovementCell ProliferationDown-RegulationEukaryotic Initiation Factor-4GG1 PhaseGene Expression Regulation, NeoplasticHumansMicroRNAsNeoplasm InvasivenessOsteosarcomaResting Phase, Cell CycleRNA, MessengerRNA, Small InterferingEIF4G2 protein, humanEukaryotic Initiation Factor-4GMicroRNAsMIRN379 microRNA, humanRNA, MessengerRNA, Small InterferingEIF4G2InvasionMicroRNA-379MigrationOsteosarcomaProliferation

Identifiers

PMID28381518
PMCPMC5434889
OpenAlexW2604632686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.